2024-10-27 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**Company Overview:** Merck & Co., Inc., is a global pharmaceutical company that develops, manufactures, and markets a wide range of prescription medicines, vaccines, and animal health products.

**Performance Summary:**

* **Cumulative Return:** 64.51% 
* **S&P 500 (VOO) Cumulative Return:** 135.48%
* **Return Difference:** -70.97% (S&P 500 outperformed MRK by 70.97%)
* **Relative Divergence:** 14.47% (MRK's performance is currently at the 14.47th percentile compared to its historical performance relative to the S&P 500).

**Recent Price Movements:**

* **Closing Price:** 105.88 (Last Market: 103.97)
* **5-day Moving Average:** 106.79
* **20-day Moving Average:** 109.79
* **60-day Moving Average:** 113.59

**Technical Indicators:**

* **RSI:** 34.23 (Indicates a potentially oversold condition)
* **PPO:** -0.25 (Indicates a bearish sentiment)
* **Delta_Previous_Relative_Divergence:** -11.7 (Negative, suggesting a recent short-term decline in price)
* **Expected Return:** 0.0% (Over the long term (2 years+), the expected return is 0% relative to the S&P 500).

**Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2023-08-07 | -2.35 | 15.04 B$ |
| 2024-08-05 | -2.35 | 15.04 B$ |

**Analysis:** 

* Recent earnings show a positive trend with an increase in both EPS and revenue. 
* The most recent earnings (2024-08-05) beat analyst estimates, exceeding expectations for EPS and revenue. 
* However, the company faces challenges in some areas, such as a decline in sales for certain key products.

**News and Recent Issues:**

* **No recent earnings news was found within the last 2 days.**
* **Market Outlook:**  
    * Merck's stock performance has been lagging compared to the broader market, potentially due to concerns about the future of its key drugs and competitive pressures in the pharmaceutical industry.
* **Analyst Opinions:**
    * Analyst opinions on Merck are mixed, with some analysts expressing optimism based on the company's strong pipeline and recent earnings, while others remain cautious due to uncertainties regarding future growth prospects.
* **Performance Highlights:**
    * Merck has faced challenges in the recent past, particularly in the face of patent expirations for some of its key drugs and increasing competition in the pharmaceutical industry. However, the company has been working to mitigate these challenges through strategic acquisitions and pipeline development.

**Overall Analysis:**

* **Merck's stock has underperformed the S&P 500 in recent years.** 
* **Technical indicators suggest a potential oversold condition and bearish sentiment.** 
* **The company's recent earnings results show a positive trend, but it faces challenges in the competitive pharmaceutical landscape.** 
* **Analysts have mixed opinions about the company's future prospects.** 
* **Investors should carefully evaluate Merck's long-term growth potential and assess its ability to overcome current challenges before making investment decisions.**

**Disclaimer:** This is a general stock analysis report based on publicly available information and should not be considered investment advice.  Investing in the stock market involves risks, and investors should conduct their own research and consult with a financial advisor before making any investment decisions. 
